Maria Diletta Pezzani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maria Diletta Pezzani has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Gervasoni
III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, 20157 Milan, Italy
3 shared publications Agostino Riva
3rd Division of Infectious Diseases, L. Sacco University Hospital, Via GB Grassi 74, 20157, Milan, Italy
2 shared publications- Chiara Resnati
Clinical Pharmacology Unit, Chemical-Clinical Analyses Laboratory, A.S.S.T Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy
2 shared publications Dario Cattaneo
Unit of Clinical Pharmacology, L. Sacco University Hospital, Milan, Italy
2 shared publications- David L. Paterson
National University of Singapore
2 shared publications - Jesús Rodríguez-Baño
Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain
2 shared publications
Latest Publications
- Open Access
- 21 November 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (47) , 2400212
Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies
To reduce antimicrobial resistance (AMR), pathogen-specific AMR burden data are crucial to guide target selection for research and development of vaccines and monoclonal antibodies (mAbs). We identified knowledge gaps through previously conducted systematic reviews, which informed a Delphi expert consultation on future AMR research priorities and harmonisation strategies to support data-driven decision-making. Consensus (≥80% agreement) on importance and feasibility of research topics was achieved in two rounds, involving 24 of 39 and 19 of 24 invited experts, respectively. Priority pathogens and resistance profiles for future research were identified: third generation cephalosporin-resistant Klebsiella pneumoniae and Escherichia coli, for bloodstream and urinary tract infections, respectively, and meticillin-resistant Staphylococcus aureus for surgical-site infections. Prioritised high-risk populations included surgical, haemato-oncological and transplant patients. Mortality and resource use were prioritised as health-economic outcomes. The importance of age-stratified data and inclusion of a non-infected comparator group were highlighted. This agenda provides guidance for future research to fill knowledge gaps and support data-driven selection of target pathogens and populations for new preventive and treatment strategies, specifically vaccines and mAbs, to effectively address the AMR burden in Europe. These research priorities are also relevant to improve the evidence base for future AMR burden estimates.
- 21 November 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (47) , 2400212
Open AccessExpert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies
To reduce antimicrobial resistance (AMR), pathogen-specific AMR burden data are crucial to guide target selection for research and development of vaccines and monoclonal antibodies (mAbs). We identified knowledge gaps through previously conducted systematic reviews, which informed a Delphi expert consultation on future AMR research priorities and harmonisation strategies to support data-driven decision-making. Consensus (≥80% agreement) on importance and feasibility of research topics was achieved in two rounds, involving 24 of 39 and 19 of 24 invited experts, respectively. Priority pathogens and resistance profiles for future research were identified: third generation cephalosporin-resistant Klebsiella pneumoniae and Escherichia coli, for bloodstream and urinary tract infections, respectively, and meticillin-resistant Staphylococcus aureus for surgical-site infections. Prioritised high-risk populations included surgical, haemato-oncological and transplant patients. Mortality and resource use were prioritised as health-economic outcomes. The importance of age-stratified data and inclusion of a non-infected comparator group were highlighted. This agenda provides guidance for future research to fill knowledge gaps and support data-driven selection of target pathogens and populations for new preventive and treatment strategies, specifically vaccines and mAbs, to effectively address the AMR burden in Europe. These research priorities are also relevant to improve the evidence base for future AMR burden estimates.
- 1 November 2017
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 50 (5) , 664-672
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
- 1 November 2017
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 50 (5) , 664-672
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
- 6 March 2017
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 73 (6) , 789-790
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir
- 6 March 2017
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 73 (6) , 789-790
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir
- Open Access
- 4 April 2016
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 20 (5) , 502-504
Abacavir-induced liver toxicity
- 4 April 2016
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 20 (5) , 502-504
Open AccessAbacavir-induced liver toxicity
- Top Cited Papers
- 1 September 2015
- Published by Springer Nature in Nature Reviews Urology
- Vol. 12 (10) , 570-584
The emerging threat of multidrug-resistant Gram-negative bacteria in urology
Antibiotic resistance in Gram-negative uropathogens is a major global concern. Worldwide, the prevalence of Enterobacteriaceae that produce extended-spectrum β-lactamase or carbapenemase enzymes continues to increase at alarming rates. Likewise, resistance to other antimicrobial agents including aminoglycosides, sulphonamides and fluoroquinolones is also escalating rapidly. Bacterial resistance has major implications for urological practice, particularly in relation to catheter-associated urinary tract infections (UTIs) and infectious complications following transrectal-ultrasonography-guided biopsy of the prostate or urological surgery. Although some new drugs with activity against Gram-negative bacteria with highly resistant phenotypes will become available in the near future, the existence of a single agent with activity against the great diversity of resistance is unlikely. Responding to the challenges of Gram-negative resistance will require a multifaceted approach including considered use of current antimicrobial agents, improved diagnostics (including the rapid detection of resistance) and surveillance, better adherence to basic measures of infection prevention, development of new antibiotics and research into non-antibiotic treatment and preventive strategies.
- 1 September 2015
- Published by Springer Nature in Nature Reviews Urology
- Vol. 12 (10) , 570-584
Top Cited PapersThe emerging threat of multidrug-resistant Gram-negative bacteria in urology
Antibiotic resistance in Gram-negative uropathogens is a major global concern. Worldwide, the prevalence of Enterobacteriaceae that produce extended-spectrum β-lactamase or carbapenemase enzymes continues to increase at alarming rates. Likewise, resistance to other antimicrobial agents including aminoglycosides, sulphonamides and fluoroquinolones is also escalating rapidly. Bacterial resistance has major implications for urological practice, particularly in relation to catheter-associated urinary tract infections (UTIs) and infectious complications following transrectal-ultrasonography-guided biopsy of the prostate or urological surgery. Although some new drugs with activity against Gram-negative bacteria with highly resistant phenotypes will become available in the near future, the existence of a single agent with activity against the great diversity of resistance is unlikely. Responding to the challenges of Gram-negative resistance will require a multifaceted approach including considered use of current antimicrobial agents, improved diagnostics (including the rapid detection of resistance) and surveillance, better adherence to basic measures of infection prevention, development of new antibiotics and research into non-antibiotic treatment and preventive strategies.
- 14 January 2014
- Published by Wolters Kluwer Health in AIDS
- Vol. 28 (2) , 285-287
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients
- 14 January 2014
- Published by Wolters Kluwer Health in AIDS
- Vol. 28 (2) , 285-287
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients